Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.

Saved in:
Bibliographic Details
Title: Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.
Authors: Post CCB; Department of Radiation Oncology, Leiden University Medical Centre, Leiden, Netherlands. Electronic address: c.c.b.post@lumc.nl., de Boer SM; Department of Radiation Oncology, Leiden University Medical Centre, Leiden, Netherlands., Powell ME; Department of Clinical Oncology, Barts Health NHS Trust, London, UK., Mileshkin L; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Katsaros D; Department of Surgical Sciences and Gynaecology, Città della Salute and S Anna Hospital, Turin, Italy., Bessette P; Department of Gynaecologic Oncology, University of Sherbrooke, Sherbrooke, QC, Canada., Leary A; Department of Cancer Medicine and Gynaecological Tumours Translational Research Lab, Gustave Roussy Cancer Centre, INSERM U981, Université Paris Saclay, Villejuif, France., Ottevanger PB; Department of Medical Oncology, Radboudumc, Nijmegen, Netherlands., McCormack M; Department of Clinical Oncology, University College Hospital London, London, UK., Khaw P; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., D'Amico R; Department of Radiation Oncology, Azienda Socio Sanitaria Territoriale, Lecco, Italy., Fyles A; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Chargari C; Department of Radiation Oncology, Gustave Roussy Cancer Campus, Paris, France., Kitchener HC; Institute of Cancer Sciences, University of Manchester, Manchester, UK., Do V; Liverpool Cancer Therapy Centre, Sydney, NSW, Australia., Lissoni A; Department of Obstetrics and Gynaecology, IRCCS San Gerardo dei Tintori, Monza, Italy., Provencher D; Department of Gynaecologic Oncology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada., Genestie C; Department of Pathology, Gustave Roussy Cancer Centre, Villejuif, France., Nijman HW; Department of Gynaecologic Oncology, University Medical Centre Groningen, Groningen, Netherlands., Whitmarsh K; Department of Radiation Oncology, The Clatterbridge Cancer Centre NHS Trust, Liverpool, UK., Jürgenliemk-Schulz IM; Department of Radiation Oncology, University Medical Centre Utrecht, Utrecht, Netherlands., Feeney A; Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UK., Lutgens LCHW; MAASTRO Clinic Radiation Oncology, Maastricht, Netherlands., Bouma J; Central Data Management and Trial Coordination, Comprehensive Cancer Centre Netherlands, Rotterdam, Netherlands., Leon-Castillo A; Department of Pathology, Leiden University Medical Centre, Leiden, Netherlands., Nout RA; Department of Radiation Oncology, Leiden University Medical Centre, Leiden, Netherlands., Putter H; Department of Medical Statistics, Leiden University Medical Centre, Leiden, Netherlands., Bosse T; Department of Pathology, Leiden University Medical Centre, Leiden, Netherlands., Creutzberg CL; Department of Radiation Oncology, Leiden University Medical Centre, Leiden, Netherlands.
Source: The Lancet. Oncology [Lancet Oncol] 2025 Oct; Vol. 26 (10), pp. 1370-1381. Date of Electronic Publication: 2025 Sep 05.
Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Comparative Study
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-5488
DOI:10.1016/S1470-2045(25)00379-1